Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 465230, 11 pages
http://dx.doi.org/10.1100/2012/465230
Review Article

Hypertonic Saline in Treatment of Pulmonary Disease in Cystic Fibrosis

Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland

Received 30 January 2012; Accepted 16 February 2012

Academic Editors: F. Becq and A. De Roux

Copyright © 2012 Emer P. Reeves et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. E. Wood, T. F. Boat, and C. F. Doershuk, “Cystic fibrosis,” American Review of Respiratory Disease, vol. 113, no. 6, pp. 833–878, 1976. View at Google Scholar · View at Scopus
  2. J. Zielenski and L. C. Tsui, “Cystic fibrosis: genotypic and phenotypic variations,” Annual Review of Genetics, vol. 29, pp. 777–807, 1995. View at Google Scholar · View at Scopus
  3. R. C. Boucher, M. J. Stutts, and M. R. Knowles, “Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation,” Journal of Clinical Investigation, vol. 78, no. 5, pp. 1245–1252, 1986. View at Google Scholar
  4. M. J. Stutts, C. M. Canessa, J. C. Olsen et al., “CFTR as a cAMP-Dependent regulator of sodium channels,” Science, vol. 269, no. 5225, pp. 847–850, 1995. View at Google Scholar · View at Scopus
  5. H. Matsui, B. R. Grubb, R. Tarran et al., “Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease,” Cell, vol. 95, no. 7, pp. 1005–1015, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. D. J. Hassett, T. R. Korfhagen, R. T. Irvin et al., “Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies,” Expert Opinion on Therapeutic Targets, vol. 14, no. 2, pp. 117–130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. B. C. Kahl, “Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease,” International Journal of Medical Microbiology, vol. 300, no. 8, pp. 514–519, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. E. D. Allen, “Cystic fibrosis: a decade of progress,” Drugs of Today, vol. 35, no. 11, pp. 835–848, 1999. View at Google Scholar · View at Scopus
  9. R. C. Boucher, “Evidence for airway surface dehydration as the initiating event in CF airway disease,” Journal of Internal Medicine, vol. 261, no. 1, pp. 5–16, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. B. P. O'Sullivan and P. Flume, “The clinical approach to lung disease in patients with cystic fibrosis,” Seminars in Respiratory and Critical Care Medicine, vol. 30, no. 5, pp. 505–513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. P. Jones and C. Wallis, “Dornase alfa for cystic fibrosis,” Cochrane Database of Systematic Reviews, vol. 3, p. CD001127, 2010. View at Google Scholar · View at Scopus
  12. P. Wark and V. M. McDonald, “Nebulised hypertonic saline for cystic fibrosis,” Cochrane Database of Systematic Reviews, no. 2, p. CD001506, 2009. View at Google Scholar · View at Scopus
  13. M. Robinson, J. A. Regnis, D. L. Bailey, M. King, G. J. Bautovich, and P. T. P. Bye, “Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 153, no. 5, pp. 1503–1509, 1996. View at Google Scholar · View at Scopus
  14. R. Amin, P. Subbarao, A. Jabar et al., “Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function,” Thorax, vol. 65, no. 5, pp. 379–383, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Ballmann and H. Von Der Hardt, “Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis,” Journal of Cystic Fibrosis, vol. 1, no. 1, pp. 35–37, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. P. A. Eng, J. Morton, J. A. Douglass, J. Riedler, J. Wilson, and C. F. Robertson, “Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis,” Pediatric Pulmonology, vol. 21, no. 2, pp. 77–83, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Suri, C. Metcalfe, B. Lees et al., “Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial,” The Lancet, vol. 358, no. 9290, pp. 1316–1321, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. M. King, B. Dasgupta, R. P. Tomkiewicz, and N. E. Brown, “Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I,” American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 1, pp. 173–177, 1997. View at Google Scholar · View at Scopus
  19. R. Tarran, B. R. Grubb, D. Parsons et al., “The CF salt controversy: in vivo observations and therapeutic approaches,” Molecular Cell, vol. 8, no. 1, pp. 149–158, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Hebestreit, U. Kersting, and H. Hebestreit, “Hypertonic saline inhibits luminal sodium channels in respiratory epithelium,” European Journal of Applied Physiology, vol. 100, no. 2, pp. 177–183, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Bergsson, E. P. Reeves, P. McNally et al., “LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline,” Journal of Immunology, vol. 183, no. 1, pp. 543–551, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. V. Havasi, C. O. Hurst, T. C. Briles et al., “Inhibitory effects of hypertonic saline on P. aeruginosa motility,” Journal of Cystic Fibrosis, vol. 7, no. 4, pp. 267–269, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. E. P. Reeves, M. Williamson, S. J. O'Neill, P. Greally, and N. G. McElvaney, “Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 11, pp. 1517–1523, 2011. View at Publisher · View at Google Scholar
  24. M. R. Elkins, M. Robinson, B. R. Rose et al., “A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis,” New England Journal of Medicine, vol. 354, no. 3, pp. 229–240, 2006. View at Publisher · View at Google Scholar
  25. S. H. Donaldson, W. D. Bennett, K. L. Zeman, M. R. Knowles, R. Tarran, and R. C. Boucher, “Mucus clearance and lung function in cystic fibrosis with hypertonic saline,” New England Journal of Medicine, vol. 354, no. 3, pp. 241–250, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. D. F. Rogers, “Mucoactive agents for airway mucus hypersecretory diseases,” Respiratory Care, vol. 52, no. 9, pp. 1176–1193, 2007. View at Google Scholar · View at Scopus
  27. M. O. Henke, A. Renner, R. M. Huber, M. C. Seeds, and B. K. Rubin, “MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions,” American Journal of Respiratory Cell and Molecular Biology, vol. 31, no. 1, pp. 86–91, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. C. B. Whitchurch, T. Tolker-Nielsen, P. C. Ragas, and J. S. Mattick, “Extracellular DNA required for bacterial biofilm formation,” Science, vol. 295, no. 5559, p. 1487, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Brandt, S. Breitenstein, H. Von Der Hardt, and B. Tummler, “DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase,” Thorax, vol. 50, no. 8, pp. 880–882, 1995. View at Google Scholar · View at Scopus
  30. C. A. Vasconcellos, P. G. Allen, M. E. Wohl, J. M. Drazen, P. A. Janmey, and T. P. Stossel, “Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin,” Science, vol. 263, no. 5149, pp. 969–971, 1994. View at Google Scholar · View at Scopus
  31. A. Kater, M. O. Henke, and B. K. Rubin, “The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin beta 4,” Annals of the New York Academy of Sciences, vol. 1112, pp. 140–153, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Schwarzenberger, D. Lei, S. M. Freeman et al., “Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma,” American Journal of Respiratory Cell and Molecular Biology, vol. 19, no. 2, pp. 333–337, 1998. View at Google Scholar · View at Scopus
  33. T. N. Hilliard, N. Regamey, J. K. Shute et al., “Airway remodelling in children with cystic fibrosis,” Thorax, vol. 62, no. 12, pp. 1074–1080, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Schulz, U. Schumacher, C. Prante, W. Sextro, and P. Prehm, “Cystic fibrosis transmembrane conductance regulator can export hyaluronan,” Pathobiology, vol. 77, no. 4, pp. 200–209, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Rahmoune, G. Lamblin, J. J. Lafitte, C. Galabert, M. Filliat, and P. Roussel, “Chondroitin sulfate in sputum from patients with cystic fibrosis and chronic bronchitis,” American Journal of Respiratory Cell and Molecular Biology, vol. 5, no. 4, pp. 315–320, 1991. View at Google Scholar · View at Scopus
  36. N. Solic, J. Wilson, S. J. Wilson, and J. K. Shute, “Endothelial activation and increased heparan sulfate expression in cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 7, pp. 892–898, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. I. A. Khatri, K. R. Bhaskar, J. T. Lamont, S. U. Sajjan, C. K. Y. Ho, and J. Forstner, “Effect of chondroitinase ABC on purulent sputum from cystic fibrosis and other patients,” Pediatric Research, vol. 53, no. 4, pp. 619–627, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Goger, Y. Halden, A. Rek et al., “Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: a model for chemokine regulation at inflammatory sites,” Biochemistry, vol. 41, no. 5, pp. 1640–1646, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. G. S. V. Kuschen, F. Coulin, C. A. Power et al., “Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses,” Biochemistry, vol. 38, no. 39, pp. 12959–12968, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Bhattacharyya, K. Solakyildirim, Z. Zhang, M. L. Chen, R. J. Linhardt, and J. K. Tobacman, “Cell-bound IL-8 increases in bronchial epithelial cells after arylsulfatase B silencing due to sequestration with chondroitin-4-sulfate,” American Journal of Respiratory Cell and Molecular Biology, vol. 42, no. 1, pp. 51–61, 2010. View at Publisher · View at Google Scholar
  41. R. C. Frates, T. T. Kaizu, and J. A. Last, “Mucus glycoproteins secreted by respiratory epithelial tissue from cystic fibrosis patients,” Pediatric Research, vol. 17, no. 1, pp. 30–34, 1983. View at Google Scholar · View at Scopus
  42. P. W. Cheng, T. F. Boat, K. Cranfill, J. R. Yankaskas, and R. C. Boucher, “Increased sulfation of glycoconjugates by cultured nasal epithelial cells from patients with cystic fibrosis,” Journal of Clinical Investigation, vol. 84, no. 1, pp. 68–72, 1989. View at Google Scholar · View at Scopus
  43. N. K. Mohapatra, P. W. Cheng, J. C. Parker et al., “Alteration of sulfation of glycoconjugates, but not sulfate transport and intracellular inorganic sulfate content in cystic fibrosis airway epithelial cells,” Pediatric Research, vol. 38, no. 1, pp. 42–48, 1995. View at Google Scholar · View at Scopus
  44. M. Robinson, A. L. Hemming, J. A. Regnis et al., “Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis,” Thorax, vol. 52, no. 10, pp. 900–903, 1997. View at Google Scholar · View at Scopus
  45. D. Dmello, R. P. Nayak, and G. M. Matuschak, “Stratified assessment of the role of inhaled hypertonic saline in reducing cystic fibrosis pulmonary exacerbations: a retrospective analysis,” British Medical Journal, vol. 1, article e000019, 2011. View at Google Scholar
  46. B. L. Laube, G. Sharpless, K. A. Carson, A. Kelly, and P. J. Mogayzel Jr, “Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis,” BMC Pulmonary Medicine, vol. 11, artice 45, 2011. View at Publisher · View at Google Scholar
  47. M. Rosenfeld, S. Davis, L. Brumback et al., “Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety,” Pediatric Pulmonology, vol. 46, no. 7, pp. 666–671, 2011. View at Publisher · View at Google Scholar
  48. E. P. Dellon, S. H. Donaldson, R. Johnson, and S. D. Davis, “Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis,” Pediatric Pulmonology, vol. 43, no. 11, pp. 1100–1106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Tarran, B. Button, M. Picher et al., “Normal and cystic fibrosis airway surface liquid homeostasis: the effects of phasic shear stress and viral infections,” Journal of Biological Chemistry, vol. 280, no. 42, pp. 35751–35759, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Enderby and I. Doull, “Hypertonic saline inhalation in cystic fibrosis–salt in the wound, or sweet success?” Archives of Disease in Childhood, vol. 92, no. 3, pp. 195–196, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. P. Buonpensiero, F. De Gregorio, A. Sepe et al., “Hyaluronic acid improves "pleasantness" and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis,” Advances in Therapy, vol. 27, no. 11, pp. 870–878, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. D. S. Armstrong, “In celebration of expectoration: induced sputum indices as outcome measures in cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 168, no. 12, pp. 1412–1413, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. S. A. Ho, R. Ball, L. J. Morrison, K. G. Brownlee, and S. P. Conway, “Clinical value of obtaining sputum and cough swab samples following inhaled hypertonic saline in children with cystic fibrosis,” Pediatric Pulmonology, vol. 38, no. 1, pp. 82–87, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. M. L. Aitken, K. E. Greene, M. R. Tonelli et al., “Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis,” Chest, vol. 123, no. 3, pp. 792–799, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. O. Tabary, S. Escotte, J. P. Couetil et al., “High susceptibility for cystic fibrosis human airway gland cells to produce IL-8 through the IκB kinase α pathway in response to extracellular NaCl content,” Journal of Immunology, vol. 164, no. 6, pp. 3377–3384, 2000. View at Google Scholar
  56. S. Hashimoto, K. Matsumoto, Y. Gon, T. Nakayama, I. Takeshita, and T. Horie, “Hyperosmolarity-induced interleukin-8 expression in human bronchial epithelial ceils through p38 mitogen-activated protein kinase,” American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 2, pp. 634–640, 1999. View at Google Scholar · View at Scopus
  57. G. E. Carpagnano, M. P. F. Barbaro, M. Cagnazzo et al., “Use of exhaled breath condensate in the study of airway inflammation after hypertonic saline solution challenge,” Chest, vol. 128, no. 5, pp. 3159–3166, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Lee, M. R. Kelher, E. E. Moore, A. Banerjee, and C. C. Silliman, “Hypertonic saline inhibits arachidonic acid priming of the human neutrophil,” Journal of Surgical Research, vol. 174, no. 1, pp. 24–28, 2012. View at Publisher · View at Google Scholar
  59. V. Schaeffer, S. Arbabi, I. A. Garcia et al., “Role of the mTOR pathway in LPS-activated monocytes: influence of hypertonic saline,” Journal of Surgical Research, vol. 171, no. 2, pp. 769–776, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. N. S. Gould, S. Gauthier, C. T. Kariya, E. Min, J. Huang, and B. J. Day, “Hypertonic saline increases lung epithelial lining fluid glutathione and thiocyanate: two protective CFTR-dependent thiols against oxidative injury,” Respiratory Research, vol. 11, article 119, 2010. View at Publisher · View at Google Scholar
  61. B. Perks and J. K. Shute, “DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: in vitro effects of mucolytics,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 5, pp. 1767–1772, 2000. View at Google Scholar · View at Scopus
  62. C. Vogelmeier and G. Doring, “Neutrophil proteinases and rhDNase therapy in cystic fibrosis,” European Respiratory Journal, vol. 9, no. 11, pp. 2193–2195, 1996. View at Publisher · View at Google Scholar · View at Scopus
  63. C. W. Frevert, M. G. Kinsella, C. Vathanaprida et al., “Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue,” American Journal of Respiratory Cell and Molecular Biology, vol. 28, no. 4, pp. 464–472, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. N. C. Kaneider, A. Djanani, and C. J. Wiedermann, “Heparan sulfate proteoglycan-involving immunomodulation by cathelicidin antimicrobial peptides LL-37 and PR-39,” The Scientific World Journal, vol. 7, pp. 1832–1838, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. W. Xiao, Y. P. Hsu, A. Ishizaka, T. Kirikae, and R. B. Moss, “Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation,” Chest, vol. 128, no. 4, pp. 2316–2326, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. W. Barańska-Rybak, A. Sonesson, R. Nowicki, and A. Schmidtchen, “Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids,” Journal of Antimicrobial Chemotherapy, vol. 57, no. 2, pp. 260–265, 2006. View at Publisher · View at Google Scholar
  67. V. Behrends, B. Ryall, X. Wang, J. G. Bundy, and H. D. Williams, “Metabolic profiling of Pseudomonas aeruginosa demonstrates that the anti-sigma factor MucA modulates osmotic stress tolerance,” Molecular BioSystems, vol. 6, no. 3, pp. 562–569, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. R. Suri, L. J. Marshall, C. Wallis, C. Metcalfe, A. Bush, and J. K. Shute, “Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 3, pp. 352–355, 2002. View at Publisher · View at Google Scholar · View at Scopus
  69. R. C. Hubbard, N. G. McElvaney, P. Birrer et al., “A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis,” New England Journal of Medicine, vol. 326, no. 12, pp. 812–815, 1992. View at Google Scholar · View at Scopus
  70. M. T. Clunes and R. C. Boucher, “Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis,” Current Opinion in Pharmacology, vol. 8, no. 3, pp. 292–299, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. E. F. Nash, A. Stephenson, F. Ratjen, and E. Tullis, “Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis,” Cochrane Database of Systematic Reviews, no. 1, p. CD007168, 2009. View at Google Scholar · View at Scopus
  72. S. Shak, D. J. Capon, R. Hellmiss, S. A. Marsters, and C. L. Baker, “Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 23, pp. 9188–9192, 1990. View at Publisher · View at Google Scholar · View at Scopus
  73. H. J. Fuchs, D. S. Borowitz, D. H. Christiansen et al., “Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis,” New England Journal of Medicine, vol. 331, no. 10, pp. 637–642, 1994. View at Publisher · View at Google Scholar
  74. B. W. Ramsey, S. J. Astley, M. L. Aitken et al., “Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis,” American Review of Respiratory Disease, vol. 148, no. 1, pp. 145–151, 1993. View at Google Scholar · View at Scopus
  75. C. Ranasinha, B. Assoufi, S. Shak et al., “Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis,” The Lancet, vol. 342, no. 8865, pp. 199–202, 1993. View at Publisher · View at Google Scholar · View at Scopus
  76. R. Suri, C. Wallis, A. Bush et al., “A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis.,” Health Technology Assessment, vol. 6, no. 34, pp. 1–60, 2002. View at Google Scholar · View at Scopus
  77. E. Daviskas, S. D. Anderson, J. D. Brannan, H. K. Chan, S. Eberl, and G. Bautovich, “Inhalation of dry-powder mannitol increases mucociliary clearance,” European Respiratory Journal, vol. 10, no. 11, pp. 2449–2454, 1997. View at Publisher · View at Google Scholar · View at Scopus
  78. E. Daviskas, S. D. Anderson, S. Eberl, H. K. Chan, and G. Bautovich, “Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis,” American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 6, pp. 1843–1848, 1999. View at Google Scholar · View at Scopus
  79. A. Jaques, E. Daviskas, J. A. Turton et al., “Inhaled mannitol improves lung function in cystic fibrosis,” Chest, vol. 133, no. 6, pp. 1388–1396, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. D. Bilton, P. Robinson, P. Cooper et al., “Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study,” European Respiratory Journal, vol. 38, no. 5, pp. 1071–1080, 2011. View at Publisher · View at Google Scholar
  81. M. Robinson, E. Daviskas, S. Eberl et al., “The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study,” European Respiratory Journal, vol. 14, no. 3, pp. 678–685, 1999. View at Publisher · View at Google Scholar · View at Scopus
  82. B. A. Kuzik, S. A. Al Qadhi, S. Kent et al., “Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants,” Journal of Pediatrics, vol. 151, no. 3, p. 266, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. F. Kellett, J. Redfern, and R. McL Niven, “Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis,” Respiratory Medicine, vol. 99, no. 1, pp. 27–31, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. F. Kellett and N. M. Robert, “Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis,” Respiratory Medicine, vol. 105, no. 12, pp. 1831–1835, 2011. View at Publisher · View at Google Scholar
  85. K. Al-Ansari, M. Sakran, B. L. Davidson, R. El Sayyed, H. Mahjoub, and K. Ibrahim, “Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants,” Journal of Pediatrics, vol. 157, no. 4, pp. 630–634, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. E. Bathoorn, J. Liesker, D. Postma, G. Koëter, A. J. M. Van Oosterhout, and H. A. M. Kerstjens, “Safety of sputum induction during exacerbations of COPD,” Chest, vol. 131, no. 2, pp. 432–438, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. J. V. Fahy, H. A. Boushey, S. C. Lazarus et al., “Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 6, pp. 1470–1475, 2001. View at Google Scholar · View at Scopus
  88. E. Rand Sutherland, “Sputum induction in COPD–it's safe, so now what do we do?” Journal of Chronic Obstructive Pulmonary Disease, vol. 3, no. 2, pp. 73–74, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. O. Toungoussova, G. B. Migliori, M. P. Foschino Barbaro et al., “Changes in sputum composition during 15 min of sputum induction in healthy subjects and patients with asthma and chronic obstructive pulmonary disease,” Respiratory Medicine, vol. 101, no. 7, pp. 1543–1548, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. A. M. Wilson, R. Leigh, F. E. Hargreave, M. M. M. Pizzichini, and E. Pizzichini, “Safety of sputum induction in moderate-to-severe smoking-related chronic obstructive pulmonary disease,” Journal of Chronic Obstructive Pulmonary Disease, vol. 3, no. 2, pp. 89–93, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. E. M. App, D. Baran, I. Dab et al., “Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis,” European Respiratory Journal, vol. 19, no. 2, pp. 294–302, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. M. R. Elkins and P. T. P. Bye, “Inhaled hypertonic saline as a therapy for cystic fibrosis,” Current Opinion in Pulmonary Medicine, vol. 12, no. 6, pp. 445–452, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. P. A. Wark, V. McDonald, and A. P. Jones, “Nebulised hypertonic saline for cystic fibrosis,” Cochrane Database of Systematic Reviews, no. 3, p. CD001506, 2005. View at Google Scholar · View at Scopus
  94. P. J. Wills, “Inhaled mannitol in cystic fibrosis,” Expert Opinion on Investigational Drugs, vol. 16, no. 7, pp. 1121–1126, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. R. C. Boucher, “Cystic fibrosis: a disease of vulnerability to airway surface dehydration,” Trends in Molecular Medicine, vol. 13, no. 6, pp. 231–240, 2007. View at Publisher · View at Google Scholar · View at Scopus